Implications of subclinical tuberculosis for vaccine trial design and global effect.

Saved in:
Bibliographic Details
Title: Implications of subclinical tuberculosis for vaccine trial design and global effect.
Authors: Churchyard GJ; Aurum Institute NPC, Houghton, Parktown, South Africa; Department of Medicine, Vanderbilt University, Nashville, TN, USA; School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. Electronic address: gchurchyard@auruminstitute.org., Houben RMGJ; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; TB Modelling Group, TB Centre, London School of Hygiene & Tropical Medicine, London, UK., Fielding K; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK., Fiore-Gartland AL; University of Washington, Seattle, WA, USA., Esmail H; MRC Clinical Trials Unit, University College London, London, UK; WHO Collaborating Centre for TB Research and Innovation, Institute for Global Health, University College London, London, UK., Grant AD; TB Centre, London School of Hygiene & Tropical Medicine, London, UK; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK; Africa Health Research Institute, KwaZulu-Natal, Durban, South Africa., Rangaka MX; MRC Clinical Trials Unit, University College London, London, UK; CIDRI-AFRICA, School of Public Health, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Behr M; McGill International TB Centre, McGill University, Montreal, QC, Canada., Garcia-Basteiro AL; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECT), Barcelona, Spain., Wong EB; Africa Health Research Institute, KwaZulu-Natal, Durban, South Africa; Division of Infectious Diseases, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Hatherill M; South African Tuberculosis Vaccine Initiative, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Mave V; Byramjee-Jeejeebhoy Government Medical College, Johns Hopkins University Clinical Research Site, Pune, India., Dagnew AF; Gates Medical Research Institute, Cambridge, MA, USA., Schmidt AC; Gates Medical Research Institute, Cambridge, MA, USA., Hanekom WA; Division of Infection and Immunity, University College London, London, UK; Africa Health Research Institute, KwaZulu-Natal, Durban, South Africa., Cobelens F; Department of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands., White RG; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; TB Modelling Group, TB Centre, London School of Hygiene & Tropical Medicine, London, UK.
Source: The Lancet. Microbe [Lancet Microbe] 2024 Oct; Vol. 5 (10), pp. 100895. Date of Electronic Publication: 2024 Jul 01.
Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-5247
DOI:10.1016/S2666-5247(24)00127-7